Cogent Biosciences, Inc.
COGT
$34.29
-$0.24-0.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.02% | -26.64% | -10.07% | -2.14% | -5.98% |
| Total Depreciation and Amortization | 1.23% | -0.52% | -0.86% | 1.67% | 2.71% |
| Total Amortization of Deferred Charges | 16.81% | -34.44% | -- | -- | -- |
| Total Other Non-Cash Items | -27.49% | 110.87% | 3.79% | 10.41% | 22.79% |
| Change in Net Operating Assets | -5,271.97% | -97.23% | -39.25% | 266.14% | -316.98% |
| Cash from Operations | -9.83% | -23.05% | -17.87% | 18.00% | -9.80% |
| Capital Expenditure | 44.64% | -1,147.69% | 50.38% | 76.05% | -629.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.82% | -107.74% | -1,814.20% | -87.07% | 13.25% |
| Cash from Investing | 88.70% | -108.18% | -1,840.13% | -87.16% | 12.50% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -2,740.65% | 200.00% | -- | -- |
| Issuance of Common Stock | -89.38% | 113.29% | 32,793.90% | -97.18% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -53.69% | -2,272.00% | -- | -- |
| Cash from Financing | -91.08% | 170.82% | 360.26% | 89.13% | 95,938.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.90% | 9,606.11% | -223.20% | -94.27% | 2,385.54% |